Striational antibodies in a paraneoplastic context

Research output: Contribution to journalArticlepeer-review

26 Scopus citations


Introduction: The clinical significance of striational antibodies (StrAbs) detected in the course of paraneoplastic antibody testing is unknown. Methods: We compared all 203 striational antibody (StrAb)-seropositive patients identified (2004-2005) during evaluation for paraneoplastic antibodies with age- and sex-matched seronegative controls. Results: Thymoma and myasthenia gravis (MG) were significantly more common among cases (P<0.0001). Cancers more rarely detected after StrAb detection were adenocarcinoma in 5 patients and sarcoma in 3 patients. All patients who had a cancer identified after StrAb testing had a titer of ≥1:7680 or a coexisting muscle AChR-binding antibody. Autoimmune disorders more commonly observed among cases (with any StrAb value) included: hypothyroidism; rheumatoid arthritis; and pernicious anemia (all P<0.05). Conclusions: StrAbs may serve as a diagnostic clue for an autoimmune diagnosis. There is a low likelihood of oncological significance in patients with StrAb titers <1:7680 without coexisting paraneoplastic Abs.

Original languageEnglish (US)
Pages (from-to)585-587
Number of pages3
JournalMuscle and Nerve
Issue number4
StatePublished - Apr 2013


  • Antibody
  • Paraneoplastic
  • Sarcoma
  • Striational
  • Thymoma

ASJC Scopus subject areas

  • Physiology
  • Clinical Neurology
  • Cellular and Molecular Neuroscience
  • Physiology (medical)


Dive into the research topics of 'Striational antibodies in a paraneoplastic context'. Together they form a unique fingerprint.

Cite this